UA78259C2 - Pyrimidine derivatives, application thereof, process for preparation (variants) thereof, pharmaceutical compositions, process for preparing pharmaceutical compositions, method for treating cancer, and method for modulating activity of receptor of insuline-like growth factor (igf-i) - Google Patents

Pyrimidine derivatives, application thereof, process for preparation (variants) thereof, pharmaceutical compositions, process for preparing pharmaceutical compositions, method for treating cancer, and method for modulating activity of receptor of insuline-like growth factor (igf-i) Download PDF

Info

Publication number
UA78259C2
UA78259C2 UA20040705367A UA20040705367A UA78259C2 UA 78259 C2 UA78259 C2 UA 78259C2 UA 20040705367 A UA20040705367 A UA 20040705367A UA 20040705367 A UA20040705367 A UA 20040705367A UA 78259 C2 UA78259 C2 UA 78259C2
Authority
UA
Ukraine
Prior art keywords
pyrimidine
ylamino
pharmaceutically acceptable
pyrazol
compound
Prior art date
Application number
UA20040705367A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UA78259C2 publication Critical patent/UA78259C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
UA20040705367A 2001-12-07 2002-03-12 Pyrimidine derivatives, application thereof, process for preparation (variants) thereof, pharmaceutical compositions, process for preparing pharmaceutical compositions, method for treating cancer, and method for modulating activity of receptor of insuline-like growth factor (igf-i) UA78259C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0104140A SE0104140D0 (sv) 2001-12-07 2001-12-07 Novel Compounds
PCT/SE2002/002221 WO2003048133A1 (en) 2001-12-07 2002-12-03 Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i)

Publications (1)

Publication Number Publication Date
UA78259C2 true UA78259C2 (en) 2007-03-15

Family

ID=20286257

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20040705367A UA78259C2 (en) 2001-12-07 2002-03-12 Pyrimidine derivatives, application thereof, process for preparation (variants) thereof, pharmaceutical compositions, process for preparing pharmaceutical compositions, method for treating cancer, and method for modulating activity of receptor of insuline-like growth factor (igf-i)

Country Status (33)

Country Link
US (3) US7521453B2 (pt)
EP (1) EP1456182B1 (pt)
JP (1) JP4347051B2 (pt)
KR (1) KR100930558B1 (pt)
CN (1) CN1289486C (pt)
AR (1) AR037736A1 (pt)
AT (1) ATE425150T1 (pt)
AU (1) AU2002365864B2 (pt)
BR (1) BR0214605A (pt)
CA (1) CA2467838C (pt)
CO (1) CO5590919A2 (pt)
CY (1) CY1109101T1 (pt)
DE (1) DE60231542D1 (pt)
DK (1) DK1456182T3 (pt)
EG (1) EG24930A (pt)
ES (1) ES2323125T3 (pt)
HK (1) HK1067631A1 (pt)
HU (1) HUP0401855A3 (pt)
IL (2) IL162376A0 (pt)
IS (1) IS7294A (pt)
MX (1) MXPA04005347A (pt)
MY (1) MY135705A (pt)
NO (1) NO327502B1 (pt)
NZ (1) NZ533130A (pt)
PL (1) PL369528A1 (pt)
PT (1) PT1456182E (pt)
RU (1) RU2317291C2 (pt)
SE (1) SE0104140D0 (pt)
SI (1) SI1456182T1 (pt)
TW (1) TWI324152B (pt)
UA (1) UA78259C2 (pt)
WO (1) WO2003048133A1 (pt)
ZA (1) ZA200404223B (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP2006514989A (ja) 2002-07-29 2006-05-18 ライジェル ファーマシューティカルズ 2,4−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
AU2004265288A1 (en) 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
DE602004032446D1 (de) * 2003-08-07 2011-06-09 Rigel Pharmaceuticals Inc 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
KR100872204B1 (ko) 2003-10-15 2008-12-09 오에스아이 파마슈티컬스, 인코포레이티드 이미다조피라진 티로신 키나제 억제제
KR20060123164A (ko) 2003-10-17 2006-12-01 아스트라제네카 아베 암 치료에 사용하기 위한 4-(피라졸-3-일아미노)피리미딘유도체
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
PL1732898T3 (pl) * 2004-03-12 2008-06-30 Analytecon Sa Pochodne tetrahydroizochinoliny i tetrahydrobenzazepiny jako inhibitory IGF-1R
EP1730128A1 (en) * 2004-03-31 2006-12-13 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
EP2305682A1 (en) * 2004-04-02 2011-04-06 OSI Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
DE102004022897A1 (de) * 2004-05-10 2005-12-08 Bayer Cropscience Ag Azinyl-imidazoazine
MY139689A (en) 2004-07-20 2009-10-30 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
ATE540035T1 (de) 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
ATE519759T1 (de) * 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
NZ555947A (en) 2005-01-19 2010-11-26 Rigel Pharmaceuticals Inc Prodrugs of 2,4-pyrimidinediamine compounds and their uses
MX2007009437A (es) * 2005-02-04 2007-08-16 Astrazeneca Ab Derivados de pirazolilaminopiridina utiles como inhibidores de cinasa.
ES2308731T3 (es) 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
GB0507347D0 (en) * 2005-04-12 2005-05-18 Astrazeneca Ab Chemical compounds
EP1877057A1 (en) * 2005-04-27 2008-01-16 AstraZeneca AB Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
KR20080015409A (ko) * 2005-05-16 2008-02-19 아스트라제네카 아베 티로신 키나제 억제제로서 유용한 피라졸릴아미노피리미딘 유도체
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
MX286273B (es) 2005-06-08 2011-05-04 Rigel Pharmaceuticals Inc Composiciones y metodos para inhibicion de la via jak.
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
TW200738281A (en) 2005-08-24 2007-10-16 Wyeth Corp Bazedoxifene acetate formulations
ES2374450T3 (es) 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
AU2006307657B2 (en) * 2005-10-28 2010-10-28 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
MX2008015657A (es) * 2006-06-09 2009-02-04 Novartis Ag Polipeptidos de factor de crecimiento similares a insulina estabilizados.
CN101506176A (zh) * 2006-06-15 2009-08-12 贝林格尔.英格海姆国际有限公司 2-苯胺基-4-氨基亚烷基氨基嘧啶
CA2654852A1 (en) * 2006-06-30 2008-01-03 Astrazeneca Ab Pyrimidine derivatives useful in the treatment of cancer
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
WO2008129255A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
CN101687863B (zh) * 2007-05-04 2012-09-12 阿斯利康(瑞典)有限公司 氨基-噻唑基-嘧啶衍生物及其治疗癌症的用途
US8178091B2 (en) 2007-05-21 2012-05-15 University Of Washington Compositions and methods for the treatment of respiratory disorders
WO2009019518A1 (en) * 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
JP2011510018A (ja) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 癌治療のためのイミダゾピラジノール誘導体
ES2396613T3 (es) * 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
AR072085A1 (es) * 2008-06-11 2010-08-04 Astrazeneca Ab Compuestos triciclicos, metodos para su preparacion, composicion farma-ceutica que los comprende y su uso en el tratamiento de enfermedades me-diadas por la actividad de las proteinas quinasas
DE102008041214A1 (de) 2008-08-13 2010-02-18 Bayer Cropscience Ag N-substituierte Azinylakyl-azincarboxamide und deren Analoge
US20110201628A1 (en) * 2008-09-30 2011-08-18 Astrazeneca Ab Heterocyclic jak kinase inhibitors
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ,エルエルシー 生体内の腫瘍細胞のemtステータスをモニターするためのinsitu法
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
MX2011011025A (es) 2009-04-20 2011-11-02 Osi Pharmaceuticals Llc Preparacion de c-piracin-metilaminas.
WO2010129740A1 (en) * 2009-05-07 2010-11-11 Osi Pharmaceuticals, Inc. Use of osi-906 for treating adrenocortical carcinoma
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
EP2519826A2 (en) 2010-03-03 2012-11-07 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2542893A2 (en) 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20130005733A1 (en) 2010-03-09 2013-01-03 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2547204A2 (de) 2010-03-18 2013-01-23 Bayer Intellectual Property GmbH Aryl- und hetarylsulfonamide als wirkstoffe gegen abiotischen pflanzenstress
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
US8546443B2 (en) * 2010-12-21 2013-10-01 Boehringer Ingelheim International Gmbh Benzylic oxindole pyrimidines
EP2671082B1 (en) 2011-02-02 2020-01-15 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
JP5886411B2 (ja) 2011-03-24 2016-03-16 ノビガ・リサーチ・エービーNoviga Research AB 新規のピリミジン誘導体
US9796791B2 (en) 2011-04-13 2017-10-24 Eastman Chemical Company Cellulose ester optical films
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
EP2776042B1 (en) 2011-11-11 2019-03-20 Duke University Combination drug therapy for the treatment of solid tumors
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
CA2941010A1 (en) 2013-02-26 2014-09-04 Triact Therapeutics, Inc. Cancer therapy
EP3044593A4 (en) 2013-09-09 2017-05-17 Triact Therapeutics, Inc. Cancer therapy
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
CN115124475B (zh) * 2022-07-11 2023-11-10 贵阳学院 一种嘧啶衍生物及其制备方法和用途
WO2024153237A1 (zh) * 2023-01-19 2024-07-25 北京普祺医药科技股份有限公司 一种igf-1r酪氨酸激酶抑制剂、药物组合物及其用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1417402A (en) * 1972-03-30 1975-12-10 Boots Co Ltd Pharmacologically active anilinobenzothiazoles
DE2426180A1 (de) * 1974-05-29 1975-12-18 Bayer Ag Verfahren zum faerben von polyurethankunststoffen
US4485284A (en) * 1982-01-11 1984-11-27 Advanced Moisture Technology, Inc. Apparatus and process for microwave moisture analysis
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CA2104053C (en) * 1992-08-31 1999-04-13 Miguel A. Cacho Automated fluid bed process
WO1997009325A1 (en) 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0970369B1 (de) * 1997-03-27 2001-09-12 Glatt Gmbh Verfahren zum überwachen und/oder steuern und regeln eines granulations-, agglomerations-, instantisierungs-, coating- und trocknungsprozesses in einer wirbelschicht oder einer bewegten schüttung durch bestimmung der produktfeuchte sowie lufttechnischer apparat zur durchführung des verfahrens
US6247246B1 (en) * 1998-05-27 2001-06-19 Denver Instrument Company Microwave moisture analyzer: apparatus and method
JP2002523497A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
CA2350801C (en) 1998-11-10 2008-05-20 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines
WO2000035455A1 (en) 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
DE19917785A1 (de) 1999-04-20 2000-10-26 Bayer Ag 2,4-Diamino-pyrimidin-Derivate
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
SI1225874T1 (sl) 1999-09-24 2006-06-30 Janssen Pharmaceutica Nv Protivirusne trdne disperzije
US6455525B1 (en) * 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
CA2400447C (en) 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
EP1282607B1 (en) 2000-05-08 2015-11-11 Janssen Pharmaceutica NV Prodrugs of hiv replication inhibiting pyrimidines
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) * 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7115739B2 (en) * 2000-09-15 2006-10-03 Vertex Pharmaceuticals Incorporated Triazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MXPA03005609A (es) 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
MXPA04001087A (es) * 2001-08-03 2004-07-08 Vertex Pharma Derivados de pirazol como inhibidores de cinasa y uso de los mismos.
EP1423380B1 (en) * 2001-08-03 2010-12-15 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
US6747461B2 (en) * 2001-10-25 2004-06-08 Pioneer Hi-Bred International, Inc. Apparatus and method for monitoring drying of an agricultural porous medium such as grain or seed
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
EP1812440B1 (en) * 2004-11-04 2010-09-22 Vertex Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
ES2308731T3 (es) * 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
NZ594385A (en) * 2005-11-03 2013-02-22 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
CA2654852A1 (en) * 2006-06-30 2008-01-03 Astrazeneca Ab Pyrimidine derivatives useful in the treatment of cancer
TW200823196A (en) * 2006-11-01 2008-06-01 Astrazeneca Ab New use
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use

Also Published As

Publication number Publication date
RU2004121029A (ru) 2006-01-10
BR0214605A (pt) 2004-09-14
NZ533130A (en) 2006-11-30
US7521453B2 (en) 2009-04-21
ZA200404223B (en) 2005-08-29
EG24930A (en) 2011-01-11
HK1067631A1 (en) 2005-04-15
NO327502B1 (no) 2009-07-27
CA2467838A1 (en) 2003-06-12
CY1109101T1 (el) 2014-07-02
SI1456182T1 (sl) 2009-08-31
CA2467838C (en) 2010-10-12
KR20050044698A (ko) 2005-05-12
SE0104140D0 (sv) 2001-12-07
PL369528A1 (en) 2005-05-02
CN1289486C (zh) 2006-12-13
CN1617858A (zh) 2005-05-18
RU2317291C2 (ru) 2008-02-20
MY135705A (en) 2008-06-30
IL162376A (en) 2011-07-31
AR037736A1 (es) 2004-12-01
HUP0401855A3 (en) 2008-06-30
IS7294A (is) 2004-06-03
JP4347051B2 (ja) 2009-10-21
ES2323125T3 (es) 2009-07-07
JP2005515998A (ja) 2005-06-02
CO5590919A2 (es) 2005-12-30
EP1456182B1 (en) 2009-03-11
DK1456182T3 (da) 2009-06-29
PT1456182E (pt) 2009-05-26
NO20042872L (no) 2004-07-06
MXPA04005347A (es) 2004-09-27
DE60231542D1 (de) 2009-04-23
KR100930558B1 (ko) 2009-12-09
EP1456182A1 (en) 2004-09-15
AU2002365864B2 (en) 2007-08-30
US20050054638A1 (en) 2005-03-10
AU2002365864A1 (en) 2003-06-17
US20120095011A1 (en) 2012-04-19
TW200409634A (en) 2004-06-16
HUP0401855A2 (hu) 2004-12-28
ATE425150T1 (de) 2009-03-15
WO2003048133A1 (en) 2003-06-12
IL162376A0 (en) 2005-11-20
TWI324152B (en) 2010-05-01
US20090131463A1 (en) 2009-05-21

Similar Documents

Publication Publication Date Title
UA78259C2 (en) Pyrimidine derivatives, application thereof, process for preparation (variants) thereof, pharmaceutical compositions, process for preparing pharmaceutical compositions, method for treating cancer, and method for modulating activity of receptor of insuline-like growth factor (igf-i)
AU2022259742B2 (en) Human plasma kallikrein inhibitors
CN101857573A (zh) 取代的喹唑啉衍生物及其作为酪氨酸激酶抑制剂的用途
ES2262137T3 (es) Derivados de pirimidinamina farmacologicamente activos y procedimientos para su preparacion.
US20220387428A1 (en) 1,4-disubstituted pyridazine analogs there of and methods for treating smn-deficiency-related conditions
UA128453C2 (uk) Гетероциклічні сполуки як імуномодулятори
CN112538078B (zh) 一类抑制dhx33解旋酶的多环化合物
ES2690790T3 (es) Derivados del ácido heterobutílico butanoico como inhibidores de LTA4H
EA029126B1 (ru) Ингибиторы ido
JP2021501123A (ja) Egfrおよび/またはher2の阻害剤ならびに使用方法
TW201249798A (en) Fluoro-pyridinone derivatives useful as antibacterial agents
TW200403060A (en) Inhibitors of tyrosine kinases
UA74206C2 (uk) Імідазоло-5-іл-2-анілінопіримідини як агенти для інгібування проліферації клітин
WO2020221038A1 (zh) 苯并噻吩类化合物及其制备方法和用途
KR20070029106A (ko) 아실하이드라존 유도체 및 키나제 신호 변환의 저해, 조절및/또는 조정에서의 이의 용도
TW202128706A (zh) 新型雜環化合物
CN110678456A (zh) 吡唑magl抑制剂
WO2022032144A1 (en) Substrate adaptor inhibitors of prmt5 and uses thereof
EP4257587A1 (en) Hydroxamate compound, preparation method therefor and application thereof
JP2014520899A (ja) 小分子によるヒト癌におけるgliタンパク質の標的化
US8546389B2 (en) Viral polymerase inhibitors
WO2022249120A1 (ko) 신규한 벤조인돌론 화합물 및 이를 포함하는 약학적 조성물
US6277871B1 (en) Inhibitors of protein isoprenyl transferases
TW200800871A (en) Novel catechol derivatives pharmaceutical compositions containing the sane and their uses
WO2016202935A1 (en) Glucose transport inhibitors